VS-4718 (previously known as PND-1186), a substituted pyridine reversible FAK inhibitor, was able to repress primary tumor mass and metastases in diverse preclinical studies, including breast cancer xenograft models [29,30,195]. Here, PTK2 is linked to neoplasm.